Table 2.

Reported cases of CRMC. Abbreviations: N, Number of Patients; M, Male; F, Female; RLE, Right Lower Extremity; LLE, Left Lower Extremity; c/b, complicated by; COPD, Chronic Obstructive Pulmonary Disease.

Author (Year)	N	Clinical History	Disseminated	Previous Macrolide Exposure	Surgery	Treatment Regimen	When CRMC identified	Clinical Outcome
Schwartz et. al (2018) [34]	4	Archived isolates from Cystic Fibrosis patients	Not described	Unknown, but likely	Not Described	Not described	Not described	Not described
Churgin et. al (2018) [33]	1	56 M scleral buckle (placed 20 years previous for retinal detachment) infection	No	Not described	Yes	linezolid, clarithromycin, IV Imipenem × 3 weeks	Prior to treatment	Improved
Mannelli et. al (2018) [41]	1	47 M prosthetic hip infection + skin lesions. Treated with Amikacin, Tigecycline, and Azithromycin initially; but hip collections grew and CRMC was identified, and patient pursued hospice	Yes	Yes; as part of initial therapy with amikacin, tigecycline, azithromycin	No	IV Amikacin, IV tigecycline, azithromycin	8 weeks into treatment	Declined further therapy after treatment failure; pursued hospice
Brown-Elliott et. al (2001) [35]	1	57 M chronic steroids (Myasthenia Gravis); multiple skin nodules on RLE; treated with clarithromycin monotherapy, developed worsening nodules and CRMC was identified and taken for debridement and given clarithromycin + tobramycin; eventually had worsening nodules again, then treated with IV linezolid effectively	No, but many lesions on RLE	Yes; as part of initial regimen; clarithromycin monotherapy	Yes; after first treatment failure	1) clarithromycin monotherapy2) Surgery + clarithromycin + tobramycin3) IV linezolid	1) 4 months into clarithromycin monotherapy2) After 2nd treatment failure after surgery	Improved with IV linezolid
Vemulapalli et. al (2001) [36]	1	65F chronic steroids (COPD), disseminated cutaneous lesions, developed resistance on clarithromycin monotherapy	Yes	Yes; as part of initial regimen of clarithromycin monotherapy	No	1) clarithromycin monotherapy2) TMP-SMZ + Ciprofloxacin	4 months into therapy when new nodules arose after initial response	Improved nodules; not fully resolved
Bañuls et. Al (2000) [37]	1	66F chronic steroids (dermatomyositis), disseminated cutaneous lesions, developed resistance on clarithromycin and ciprofloxacin	Yes	Yes; as part of initial regimen of clarithromycin monotherapy	No	1) clarithromycin and ciprofloxacin2) minocycline and clarithromycin	2 months into therapy when nodules recurred	Improved skin lesions; died of metastatic vulvar cancer
Driscoll et. al (1997) [38]	1	66F chronic steroids (pemphigus vulgaris), multiple lesions on L lower extremity (LLE); developed resistance on clarithromycin monotherapy	No, but multiple lesions on LLE	Yes; as part of second regimen of clarithromycin monotherapy	No	1) Minocycline (no response)2) Clarithromycin (rapid response, then recurrence)3) Erythromycin4) tobramycin (developed AKI)5) palliative ciprofloxacin and azithromycin (no improvement)	2 months into therapy when nodules recurred	Did not improve
Tebas et al. (1995) [39]	1	60 M orthotopic heart transplant c/b rejection (prednisone, azathioprine, cyclosporin), bilateral arm lesions, developed resistance on clarithromycin monotherapy	Yes	Yes; as part of initial regimen of clarithromycin monotherapy	No	1) clarithromycin monotherapy2) imipenem and tobramycin (tobramycin stopped due to AKI)	3 months on therapy	All antibiotic therapy was stopped due to lack of effective options, died of other causes
Wallace et al. (1993) [40]	1	39F with multiple sclerosis on immunosuppression (not specified), disseminated cutaneous disease, developed resistance after self-discontinuing clarithromycin monotherapy at 3.5 months	Yes	Yes; as part of trial regimen of clarithromycin monotherapy	No	Clarithromycin monotherapy, then self-discontinued	1 month after self-discontinuing her therapy	Not provided